

FINAL

Depression in adults

[Supplement B3] Forest plots for first-line
treatment of more severe depression

NICE guideline NG222

Evidence review supplement

June 2022

Final

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2022. All rights reserved. Subject to [Notice of Rights](#).

ISBN: 978-1-4731-4622-8

Contents

Contents	4
Forest plots for first-line treatment of more severe depression	24
Appendix E – Forest plots.....	24
More severe: Behavioural activation (BA) individual versus no treatment.....	24
Figure 1: Remission (ITT).....	24
Figure 2: Discontinuation (any reason)	24
Figure 3: Depression symptomatology at 9-month follow-up.....	24
Figure 4: Remission at 9-month follow-up (ITT).....	24
More severe: Behavioural therapies individual versus cognitive and cognitive behavioural therapies individual	25
Figure 5: Depression symptomatology endpoint.....	25
Figure 6: Depression symptomatology change score	25
Figure 7: Remission (ITT).....	25
Figure 8: Discontinuation (any reason)	26
Figure 9: Depression symptomatology at 2-6 month follow-up.....	26
Figure 10: Interpersonal functioning endpoint.....	26
More severe: Behavioural activation (BA) individual versus any psychotherapy	26
Figure 11: Depression symptomatology endpoint.....	26
Figure 12: Depression symptomatology change score	27
Figure 13: Remission (ITT).....	27
Figure 14: Response (ITT)	27
Figure 15: Discontinuation (any reason)	27
Figure 16: Quality of life endpoint	27
Figure 18: Quality of life mental health component endpoint	28
More severe: Behavioural activation (BA) individual versus sertraline	28
Figure 19: Remission (ITT).....	28
Figure 20: Response (ITT)	28
Figure 22: Remission at 8-month follow-up (ITT).....	28
Figure 23: Response at 8-month follow-up (ITT).....	29
More severe: Behavioural activation (BA) individual + amitriptyline versus amitriptyline	29
Figure 24: Depression symptomatology endpoint.....	29
Figure 25: Depression symptomatology change score	29
Figure 26: Depression symptomatology at 6-month follow-up.....	29
More severe: Behavioural activation (BA) individual + any AD versus counselling + any AD	30
Figure 27: Depression symptomatology endpoint.....	30
Figure 28: Depression symptomatology change score	30
Figure 29: Discontinuation (any reason)	30

More severe: Behavioural activation (BA) individual + amitriptyline versus progressive muscle relaxation + amitriptyline	30
Figure 30: Depression symptomatology endpoint	30
Figure 31: Depression symptomatology change score	30
Figure 32: Depression symptomatology at 6-month follow-up.....	31
More severe: Coping with Depression course (group) versus waitlist	31
Figure 33: Discontinuation (any reason)	31
More severe: Cognitive and cognitive behavioural therapies individual versus no treatment.....	32
Figure 34: Depression symptomatology endpoint	32
Figure 35: Depression symptomatology change score	32
Figure 36: Remission (ITT).....	32
Figure 37: Discontinuation (any reason)	32
Figure 38: Depression symptomatology at 3-6 month follow-up.....	33
Figure 39: Depression symptomatology at 9-month follow-up.....	33
Figure 40: Remission at 6-9 month follow-up (ITT).....	34
Figure 41: Functional impairment endpoint.....	34
Figure 42: Functional impairment at 6-month follow-up	34
More severe: Cognitive and cognitive behavioural therapies individual versus waitlist..	35
Figure 43: Depression symptomatology endpoint	35
Figure 44: Depression symptomatology change score	35
Figure 45: Discontinuation (any reason)	35
More severe: Cognitive and cognitive behavioural therapies individual versus TAU	36
Figure 46: Depression symptomatology endpoint	36
Figure 47: Depression symptomatology change score	36
Figure 48: Remission (ITT).....	36
Figure 49: Discontinuation (any reason)	37
Figure 50: Depression symptomatology at 8-month follow-up.....	37
Figure 51: Interpersonal problems endpoint	37
Figure 52: Interpersonal problems at 8-month follow-up	37
Figure 53: Functional impairment endpoint.....	38
More severe: CBT individual (15 sessions or over) versus IPT	38
Figure 54: Depression symptomatology endpoint	38
Figure 55: Depression symptomatology change score	38
Figure 56: Remission (ITT).....	38
Figure 57: Discontinuation (any reason)	39
Figure 58: Global functioning endpoint	39
Figure 59: Interpersonal problems endpoint	39
More severe: CBT individual (under 15 sessions) versus counselling.....	39
Figure 60: Depression symptomatology endpoint	39
Figure 61: Depression symptomatology change score	39

Figure 62: Discontinuation (any reason)	40
Figure 63: Depression symptomatology at 3-month follow-up.....	40
Figure 64: Depression symptomatology at 8-9 month follow-up.....	40
Figure 65: Interpersonal problems endpoint	40
Figure 66: Interpersonal problems at 8-month follow-up	40
More severe: CBT individual (under 15 sessions) versus computerised-CBT (CCBT) ..	41
Figure 67: Depression symptomatology endpoint.....	41
Figure 68: Depression symptomatology change score	41
Figure 69: Discontinuation (any reason)	41
Figure 70: Depression symptomatology at 3-month follow-up.....	41
Figure 71: Depression symptomatology at 9-month follow-up.....	41
Figure 72: Remission at 9-month follow-up (ITT).....	42
More severe: Cognitive and cognitive behavioural therapies individual versus self- help with support	42
Figure 73: Depression symptomatology endpoint.....	42
Figure 74: Depression symptomatology change score	42
Figure 75: Remission (ITT).....	43
Figure 76: Discontinuation (any reason).....	43
Figure 77: Depression symptomatology at 3-month follow-up.....	43
Figure 78: Depression symptomatology at 6-month follow-up.....	44
Figure 79: Depression symptomatology change score at 3-month follow-up	44
Figure 80: Depression symptomatology change score at 6-month follow-up	44
Figure 81: Quality of life endpoint	44
Figure 82: Global functioning endpoint	44
Figure 83: Global functioning at 3-month follow-up.....	45
Figure 84: Global functioning at 6-month follow-up.....	45
Figure 85: Interpersonal problems endpoint	45
Figure 86: Interpersonal problems at 3-month follow-up	45
Figure 87: Interpersonal problems at 6-month follow-up	46
More severe: Dialectical behavioural therapy (DBT) individual versus CBT group (under 15 sessions).....	46
Figure 88: Depression symptomatology endpoint.....	46
Figure 89: Depression symptomatology change score	46
More severe: Cognitive and cognitive behavioural therapies individual versus SSRI	47
Figure 90: Depression symptomatology endpoint.....	47
Figure 91: Depression symptomatology change score	47
Figure 92: Remission (ITT).....	47
Figure 93: Discontinuation (any reason)	48
Figure 94: Quality of life endpoint	48
Figure 95: Functional impairment endpoint.....	48
More severe: Cognitive and cognitive behavioural therapies individual versus TCA	49

Figure 96: Depression symptomatology endpoint	49
Figure 97: Depression symptomatology change score	49
Figure 98: Remission (ITT).....	50
Figure 99: Discontinuation (any reason)	51
Figure 100: Depression symptomatology at 1-month follow-up.....	51
Figure 101: Depression symptomatology at 12-month follow-up.....	51
Figure 102: Remission at 12-month follow-up (ITT)	52
Figure 103: Global functioning endpoint	52
Figure 104: Interpersonal problems endpoint	52
More severe: CBT individual (15 sessions or over) versus venlafaxine.....	52
Figure 105: Depression symptomatology endpoint	52
Figure 106: Depression symptomatology change score	52
Figure 107: Remission (ITT).....	53
Figure 108: Response (ITT).....	53
Figure 109: Discontinuation (any reason)	53
More severe: CBT individual (15 sessions or over) versus any AD.....	53
Figure 110: Depression symptomatology endpoint	53
Figure 111: Depression symptomatology change score	53
Figure 112: Remission (ITT)	54
Figure 113: Discontinuation (any reason)	54
More severe: CBT individual (15 sessions or over) versus pill placebo.....	54
Figure 114: Depression symptomatology endpoint	54
Figure 115: Depression symptomatology change score	54
Figure 116: Remission (ITT).....	54
Figure 117: Discontinuation (any reason)	55
Figure 118: Global functioning endpoint	55
Figure 119: Interpersonal problems endpoint	55
More severe: Cognitive and cognitive behavioural therapies individual + AD versus AD	56
Figure 120: Depression symptomatology endpoint	56
Figure 121: Depression symptomatology change score	57
Figure 122: Remission (ITT).....	57
Figure 123: Response (ITT).....	58
Figure 124: Discontinuation due to SE	58
Figure 125: Discontinuation due to any reason (including SE).....	59
Figure 126: Depression symptomatology at 3-month follow-up.....	60
Figure 127: Depression symptomatology at 6-12 month follow-up.....	60
Figure 128: Global functioning endpoint	60
Figure 129: Functional impairment endpoint.....	60
More severe: Cognitive and cognitive behavioural therapies individual + SSRI versus TAU	61

Figure 130: Depression symptomatology endpoint	61
Figure 131: Depression symptomatology change score	61
Figure 132: Remission (ITT)	61
Figure 133: Discontinuation due to any reason	62
Figure 134: Quality of life endpoint	62
Figure 135: Functional impairment endpoint	62
More severe: CBT group (under 15 sessions) versus no treatment	62
Figure 136: Depression symptomatology endpoint	62
Figure 137: Depression symptomatology change score	63
Figure 138: Depression symptomatology at 6-month follow-up	63
More severe: CBT group (under 15 sessions) versus waitlist	63
Figure 139: Depression symptomatology endpoint	63
Figure 140: Depression symptomatology change score	63
Figure 141: Discontinuation due to any reason	63
More severe: CBT group (under 15 sessions) versus TAU	64
Figure 142: Depression symptomatology endpoint	64
Figure 143: Depression symptomatology change score	64
Figure 144: Discontinuation due to any reason	64
Figure 145: Remission at 9-month follow-up (ITT)	64
More severe: CBT group (under 15 sessions) versus behavioural activation (BA) group	64
Figure 146: Depression symptomatology endpoint	64
Figure 147: Discontinuation due to any reason	65
Figure 148: Depression symptomatology at 1-month follow-up	65
More severe: CBT group (under 15 sessions) versus cognitive bibliotherapy	65
Figure 149: Depression symptomatology endpoint	65
Figure 150: Depression symptomatology change score	65
Figure 151: Discontinuation due to any reason	65
Figure 152: Depression symptomatology at 2-month follow-up	66
More severe: CBT group (under 15 sessions) versus cognitive bibliotherapy with support	66
Figure 153: Depression symptomatology endpoint	66
Figure 154: Depression symptomatology change score	66
Figure 155: Discontinuation due to any reason	66
Figure 156: Depression symptomatology at 2-month follow-up	66
More severe: CBT group (under 15 sessions) versus fluoxetine	67
Figure 157: Depression symptomatology endpoint	67
Figure 158: Remission (ITT)	67
Figure 159: Response (ITT)	67
Figure 160: Discontinuation due to any reason	67
Figure 161: Depression symptomatology at 3-month follow-up	67

Figure 162: Remission at 3-month follow-up (ITT)	68
Figure 163: Response at 3-month follow-up (ITT).....	68
Figure 164: Quality of life endpoint	68
Figure 165: Quality of life at 3-month follow-up.....	68
More severe: CBT group (under 15 sessions) versus any AD	68
Figure 166: Depression symptomatology endpoint	68
Figure 167: Depression symptomatology change score	69
Figure 168: Discontinuation due to any reason.....	69
Figure 169: Remission at 9-month follow-up (ITT).....	69
More severe: CBT group (under 15 sessions) + any AD.....	69
Figure 170: Depression symptomatology endpoint	69
Figure 171: Depression symptomatology change score	69
Figure 172: Discontinuation due to SE	70
Figure 173: Discontinuation due to any reason including SE	70
Figure 174: Depression symptomatology at 6-month follow-up.....	70
More severe: Problem solving individual versus waitlist.....	70
Figure 175: Depression symptomatology endpoint	70
Figure 176: Depression symptomatology change score	70
Figure 177: Discontinuation due to any reason.....	71
Figure 178: Depression symptomatology at 2-month follow-up.....	71
More severe: Problem solving individual versus attention placebo	71
Figure 179: Depression symptomatology endpoint	71
Figure 180: Depression symptomatology change score	71
Figure 181: Discontinuation due to any reason.....	71
Figure 182: Depression symptomatology at 3-month follow-up.....	71
Figure 183: Depression symptomatology at 6-month follow-up.....	72
Figure 184: Functional impairment endpoint.....	72
Figure 185: Functional impairment at 3-month follow-up	72
Figure 186: Functional impairment at 6-month follow-up	72
More severe: Problem solving individual versus counselling.....	72
Figure 187: Depression symptomatology at endpoint	72
Figure 188: Depression symptomatology change score	72
Figure 189: Remission (ITT).....	73
Figure 190: Response (ITT).....	73
Figure 191: Discontinuation due to any reason.....	73
Figure 192: Functional impairment at endpoint.....	73
More severe: Problem solving individual versus any SSRI	74
Figure 193: Depression symptomatology endpoint	74
Figure 194: Remission (ITT).....	74
Figure 195: Discontinuation due to any reason.....	74

Figure 196: Depression symptomatology at 9-month follow-up.....	74
Figure 197: Remission at 9-month follow-up (ITT).....	74
More severe: Problem solving individual versus amitriptyline	75
Figure 198: Depression symptomatology endpoint.....	75
Figure 199: Depression symptomatology change score	75
Figure 200: Remission (ITT).....	75
Figure 201: Discontinuation due to any reason.....	75
More severe: Problem solving individual versus pill placebo.....	75
Figure 202: Depression symptomatology endpoint.....	75
Figure 203: Depression symptomatology change score	76
Figure 204: Remission (ITT).....	76
Figure 205: Discontinuation due to any reason.....	76
More severe: Problem solving individual + any SSRI versus any SSRI	76
Figure 206: Depression symptomatology endpoint.....	76
Figure 207: Remission (ITT).....	76
Figure 208: Discontinuation due to SE	77
Figure 209: Discontinuation due any reason including SE	77
Figure 210: Depression symptomatology at 9-month follow-up.....	77
Figure 211: Remission at 9-month follow-up (ITT).....	77
More severe: Problem solving group versus waitlist	77
Figure 212: Depression symptomatology endpoint.....	77
Figure 213: Depression symptomatology change score	78
Figure 214: Remission (ITT).....	78
Figure 215: Discontinuation due to any reason.....	78
More severe: Counselling versus no treatment.....	78
Figure 216: Depression symptomatology endpoint.....	78
Figure 217: Depression symptomatology change score	78
Figure 218: Response (ITT).....	79
Figure 219: Discontinuation due to any reason.....	79
Figure 220: Depression symptomatology at 5-month follow-up.....	79
Figure 221: Response at 5-month follow-up (ITT).....	79
Figure 222: Functional impairment endpoint.....	79
Figure 223: Functional impairment at 5-month follow-up	79
More severe: Counselling versus TAU.....	80
Figure 224: Depression symptomatology endpoint.....	80
Figure 225: Depression symptomatology change score	80
Figure 226: Discontinuation due to any reason.....	80
Figure 227: Depression symptomatology at 8-month follow-up.....	80
Figure 228: Interpersonal problems endpoint	80
Figure 229: Interpersonal problems at 8-month follow-up	80

More severe: Counselling versus computerised-CBT (CCBT)	81
Figure 230: Depression symptomatology endpoint	81
Figure 231: Depression symptomatology change score	81
Figure 232: Depression symptomatology at 3-month follow-up.....	81
Figure 233: Depression symptomatology at 9-month follow-up.....	81
More severe: Counselling versus any AD	81
Figure 234: Depression symptomatology endpoint	81
Figure 235: Remission (ITT).....	82
Figure 236: Discontinuation due to any reason.....	82
Figure 237: Depression symptomatology at 10-month follow-up.....	82
Figure 238: Remission at 10 months follow-up (ITT)	82
More severe: IPT versus any AD	82
Figure 239: Depression symptomatology endpoint	82
Figure 240: Depression symptomatology change score	83
More severe: Interpersonal counselling individual versus any SSRI	83
Figure 241: Remission (ITT).....	83
Figure 242: Discontinuation due to any reason.....	83
More severe: IPT versus imipramine	83
Figure 243: Depression symptomatology endpoint	83
Figure 244: Depression symptomatology change score	83
Figure 245: Remission (ITT).....	84
Figure 246: Discontinuation due to any reason.....	84
Figure 247: Global functioning endpoint	84
Figure 248: Interpersonal problems endpoint	84
More severe: IPT versus pill placebo	84
Figure 249: Depression symptomatology endpoint	84
Figure 250: Depression symptomatology change score	85
Figure 251: Remission (ITT).....	85
Figure 252: Discontinuation due to any reason.....	85
Figure 253: Global functioning endpoint	85
Figure 254: Interpersonal problems endpoint	85
More severe: IPT + AD versus AD.....	86
Figure 255: Depression symptomatology endpoint	86
Figure 256: Depression symptomatology change score	86
Figure 257: Remission (ITT).....	87
Figure 258: Discontinuation due to SE	87
Figure 259: Discontinuation due to any reason including SE	88
Figure 260: Remission at 3-month follow-up (ITT).....	88
Figure 262: Global functioning endpoint	89
More severe: IPT + any AD versus psychoeducation group + any AD.....	89

Figure 263: Depression symptomatology change score	89
Figure 264: Remission (ITT).....	89
Figure 265: Discontinuation due to any reason.....	89
Figure 266: Remission at 3-month follow-up (ITT).....	89
Figure 267: Remission at 9-month follow-up (ITT).....	90
More severe: Computerised-CBT (CCBT) versus no treatment	90
Figure 268: Depression symptomatology endpoint.....	90
Figure 269: Depression symptomatology change score	90
Figure 270: Discontinuation due to any reason.....	90
Figure 271: Depression symptomatology at 3-month follow-up.....	90
Figure 272: Depression symptomatology at 9-month follow-up.....	91
Figure 273: Remission at 9-month follow-up (ITT).....	91
Figure 274: Quality of life endpoint	91
More severe: Self-help versus waitlist	91
Figure 275: Depression symptomatology endpoint.....	91
Figure 276: Depression symptomatology change score	92
Figure 277: Remission (ITT).....	92
Figure 278: Response (ITT).....	92
Figure 279: Discontinuation due to any reason.....	93
Figure 280: Functional impairment endpoint.....	93
More severe: Computerised-CBT (CCBT) versus enhanced TAU	93
Figure 281: Depression symptomatology endpoint.....	93
Figure 282: Discontinuation due to any reason.....	93
Figure 283: Depression symptomatology at 6-month follow-up.....	94
Figure 284: Quality of life endpoint	94
Figure 285: Quality of life at 6-month follow-up.....	94
Figure 286: Quality of life at 12-month follow-up.....	94
More severe: Computerised attentional bias modification versus attention placebo.....	94
Figure 287: Depression symptomatology endpoint.....	94
Figure 288: Depression symptomatology change score	94
More severe: Self-help + AD versus AD	95
Figure 289: Depression symptomatology endpoint.....	95
Figure 290: Remission (ITT).....	95
Figure 291: Response (ITT).....	95
Figure 292: Discontinuation due to any reason.....	95
Figure 293: Quality of life physical health component endpoint	96
Figure 294: Quality of life mental health component endpoint.....	96
Figure 295: Depression symptomatology at 8-month follow-up.....	96
Figure 296: Depression symptomatology at 20-month follow-up.....	96
Figure 297: Remission at 8-month follow-up (ITT).....	96

Figure 298: Remission at 20-month follow-up (ITT)	97
Figure 299: Quality of life physical health component at 8-month follow-up	97
Figure 300: Quality of life mental health component at 8-month follow-up	97
Figure 301: Quality of life physical health component at 20-month follow-up	97
Figure 302: Quality of life mental health component at 20-month follow-up	97
More severe: Computerised-CBT (CCBT) with support versus no treatment	98
Figure 303: Depression symptomatology endpoint	98
Figure 304: Depression symptomatology change score	98
Figure 305: Remission (ITT)	98
Figure 306: Discontinuation due to any reason	98
Figure 307: Quality of life endpoint	98
More severe: Self-help with support versus waitlist	99
Figure 308: Depression symptomatology endpoint	99
Figure 309: Depression symptomatology change score	99
Figure 310: Remission (ITT)	99
Figure 311: Response (ITT)	100
Figure 312: Discontinuation due to any reason	100
Figure 313: Quality of life endpoint	100
Figure 314: Functional impairment endpoint	100
Figure 315: Sleeping difficulties endpoint	101
More severe: Self-help with support versus self-help (without support)	101
Figure 316: Depression symptomatology endpoint	101
Figure 317: Depression symptomatology change score	101
Figure 318: Remission (ITT)	101
Figure 319: Discontinuation due to any reason	102
Figure 320: Depression symptomatology at 2-3 month follow-up	102
Figure 321: Depression symptomatology at 6-month follow-up	102
Figure 322: Quality of life endpoint	102
Figure 323: Quality of life at 3-month follow-up	103
Figure 324: Quality of life at 6-month follow-up	103
More severe: Short-term psychodynamic psychotherapies individual versus any psychotherapy	103
Figure 325: Depression symptomatology endpoint	103
Figure 326: Depression symptomatology change score	103
Figure 327: Discontinuation due to any reason	103
More severe: Short-term psychodynamic psychotherapy individual versus cognitive and cognitive behavioural therapies individual	104
Figure 328: Depression symptomatology endpoint	104
Figure 329: Depression symptomatology change score	104
Figure 330: Remission (ITT)	104
Figure 331: Discontinuation due to any reason	105

Figure 332: Quality of life endpoint	105
Figure 333: Quality of life physical health component endpoint	105
Figure 334: Quality of life mental health component endpoint.....	105
Figure 335: Interpersonal problems endpoint	106
Figure 336: Remission at 3-month follow-up (ITT)	106
More severe: Dynamic interpersonal therapy (DIT) individual versus cognitive bibliotherapy with support.....	106
Figure 337: Depression symptomatology endpoint	106
Figure 338: Depression symptomatology change score	106
Figure 339: Remission (ITT).....	106
Figure 340: Discontinuation due to any reason.....	107
Figure 341: Quality of life endpoint	107
Figure 342: Interpersonal problems endpoint	107
More severe: Short-term psychodynamic psychotherapies individual versus fluoxetine.....	107
Figure 343: Depression symptomatology change score	107
Figure 344: Remission (ITT).....	107
Figure 345: Discontinuation due to any reason.....	108
Figure 346: Global functioning change score.....	108
More severe: Short-term psychodynamic psychotherapy individual + any AD versus any AD	108
Figure 347: Depression symptomatology endpoint.....	108
Figure 348: Depression symptomatology change score	108
Figure 349: Quality of life endpoint	108
More severe: Short-term psychodynamic psychotherapy individual + AD versus counselling + AD	109
Figure 350: Depression symptomatology endpoint.....	109
Figure 351: Depression symptomatology change score	109
Figure 352: Remission (ITT).....	109
Figure 353: Response (ITT).....	110
Figure 354: Discontinuation due to any reason.....	110
Figure 355: Depression symptomatology at 3-6 month follow-up.....	110
Figure 356: Remission at 3-6 month follow-up (ITT)	111
Figure 357: Response at 3-6 month follow-up (ITT).....	111
Figure 358: Functional impairment endpoint.....	111
Figure 359: Functional impairment at 3-month follow-up	111
More severe: Short-term psychodynamic psychotherapy group versus cognitive and cognitive behavioural therapies group	112
Figure 360: Remission (ITT).....	112
More severe: Long-term psychodynamic psychotherapy individual versus fluoxetine .	112
Figure 361: Depression symptomatology endpoint.....	112

Figure 362: Remission (ITT).....	112
Figure 363: Discontinuation due to any reason.....	112
More severe: Long-term psychodynamic psychotherapy individual + fluoxetine versus fluoxetine	113
Figure 364: Depression symptomatology endpoint.....	113
Figure 365: Remission (ITT).....	113
Figure 366: Discontinuation due to any reason.....	113
More severe: Music therapy group versus no treatment	113
Figure 367: Depression symptomatology at endpoint	113
Figure 368: Depression symptomatology change score	113
Figure 369: Discontinuation due to any reason.....	114
More severe: Peer support group versus any AD	114
Figure 370: Depression symptomatology endpoint.....	114
Figure 371: Depression symptomatology change score	114
Figure 372: Remission (ITT).....	114
Figure 373: Discontinuation due to any reason.....	114
Figure 374: Depression symptomatology at 6-month follow-up.....	115
Figure 375: Remission at 6-month follow-up (ITT).....	115
More severe: Peer support group + any AD versus any AD.....	115
Figure 376: Depression symptomatology endpoint.....	115
Figure 377: Depression symptomatology change score	115
Figure 378: Remission (ITT).....	115
Figure 379: Discontinuation due to any reason.....	115
Figure 380: Depression symptomatology at 6-month follow-up.....	116
Figure 381: Remission at 6-month follow-up (ITT).....	116
More severe: Psychoeducation group versus no treatment	116
Figure 382: Depression symptomatology endpoint.....	116
Figure 383: Depression symptomatology change score	116
Figure 384: Discontinuation due to any reason.....	116
More severe: Psychoeducation group + any AD versus any AD	117
Figure 385: Depression symptomatology change score	117
Figure 386: Remission (ITT).....	117
Figure 387: Discontinuation due to any reason.....	117
Figure 388: Remission at 3-month follow-up (ITT).....	117
Figure 389: Remission at 9-month follow-up (ITT).....	117
More severe: Mindfulness-based cognitive therapy (MBCT) group versus no treatment.....	118
Figure 390: Depression symptomatology endpoint.....	118
Figure 391: Depression symptomatology change score	118
More severe: Progressive muscle relaxation + amitriptyline versus amitriptyline	118
Figure 392: Depression symptomatology endpoint.....	118

Figure 393: Depression symptomatology change score	118
Figure 394: Depression symptomatology at 6-month follow-up.....	118
More severe: SSRIs versus no treatment	119
Figure 395: Depression symptomatology endpoint.....	119
Figure 396: Depression symptomatology change score	119
Figure 397: Discontinuation due to any reason.....	119
Figure 398: Quality of life physical health component endpoint	119
Figure 399: Quality of life mental health component endpoint.....	120
More severe: SSRIs versus placebo.....	121
Figure 400: Depression symptomatology endpoint.....	121
Figure 401: Depression symptomatology change score	122
Figure 402: Remission (ITT).....	123
Figure 403: Response (ITT).....	124
Figure 404: Discontinuation due to SE	125
Figure 405: Discontinuation due to any reason including SE	126
Figure 406: Remission at 12-month follow-up (ITT)	127
Figure 407: Quality of life change score	127
Figure 408: Global functioning endpoint	127
Figure 409: Functional impairment change score	127
Figure 410: Sleeping difficulties change score endpoint	127
More severe: SSRIs versus TCAs	128
Figure 411: Depression symptomatology endpoint.....	128
Figure 412: Depression symptomatology change score	130
Figure 413: Remission (ITT).....	131
Figure 414: Response (ITT).....	132
Figure 415: Discontinuation due to SE	133
Figure 416: Discontinuation due to any reason including SE	134
Figure 417: Sleep endpoint	135
Figure 418: Functional impairment endpoint.....	135
More severe: Fluoxetine + long-term psychodynamic psychotherapy individual versus long-term psychodynamic psychotherapy individual.....	135
Figure 419: Depression symptomatology endpoint.....	135
Figure 420: Remission (ITT).....	135
Figure 421: Discontinuation due to any reason.....	135
More severe: SSRI + psych intervention versus placebo + psych intervention.....	136
Figure 422: Depression symptomatology endpoint.....	136
Figure 423: Depression symptomatology change score	136
Figure 424: Remission (ITT).....	136
Figure 425: Discontinuation due to SE	137
Figure 426: Discontinuation due to any reason including SE	137

More severe: Sertraline + supervised high intensity exercise individual versus supervised high intensity exercise individual	137
Figure 427: Depression symptomatology endpoint	137
Figure 428: Depression symptomatology change score	137
More severe: Fluoxetine + bright light therapy versus bright light therapy	138
Figure 429: Depression symptomatology change score	138
Figure 430: Remission (ITT)	138
Figure 431: Response (ITT)	138
Figure 432: Discontinuation due to SE	138
Figure 433: Discontinuation due to any reason including SE	138
More severe: TCAs versus placebo	139
Figure 434: Depression symptomatology endpoint	139
Figure 435: Depression symptomatology change score	140
Figure 436: Remission (ITT)	140
Figure 437: Response (ITT)	141
Figure 438: Discontinuation due to SE	142
Figure 439: Discontinuation due to any reason including SE	144
Figure 440: Depression symptomatology at 6-month follow-up	145
Figure 441: Global functioning endpoint	145
Figure 442: Quality of life change score	145
Figure 443: Quality of life physical health component endpoint	145
Figure 444: Quality of life mental health component endpoint	145
Figure 445: Interpersonal problems endpoint	146
More severe: TCA + psych intervention versus psych intervention	146
Figure 446: Depression symptomatology endpoint	146
Figure 447: Depression symptomatology change score	146
Figure 448: Remission (ITT)	147
Figure 449: Discontinuation due to any reason	147
Figure 450: Depression symptomatology at 1-month follow-up	147
Figure 451: Depression symptomatology at 12-month follow-up	147
Figure 452: Global functioning endpoint	148
More severe: TCA + psych intervention versus placebo + psych intervention	148
Figure 453: Depression symptomatology endpoint	148
Figure 454: Depression symptomatology change score	148
Figure 455: Remission (ITT)	149
Figure 456: Response (ITT)	149
Figure 457: Discontinuation due to SE	149
Figure 458: Discontinuation due to any reason including SE	150
Figure 459: Depression symptomatology at 1-month follow-up	150
Figure 460: Depression symptomatology at 6-month follow-up	150

More severe: SNRIs versus placebo	150
Figure 461: Depression symptomatology endpoint	150
Figure 462: Depression symptomatology change score	151
Figure 463: Remission (ITT)	152
Figure 464: Response (ITT).....	153
Figure 465: Discontinuation due to SE	154
Figure 466: Discontinuation due to any reason including SE	155
Figure 467: Functional impairment change score	155
More severe: SNRIs versus TCAs	156
Figure 468: Depression symptomatology endpoint	156
Figure 469: Depression symptomatology change score	156
Figure 470: Remission (ITT).....	157
Figure 471: Response (ITT).....	157
Figure 472: Discontinuation due to SE	158
Figure 473: Discontinuation due to any reason including SE	159
More severe: SNRIs versus SSRIs	160
Figure 474: Depression symptomatology endpoint	160
Figure 475: Depression symptomatology change score	161
Figure 476: Remission (ITT)	162
Figure 477: Response (ITT).....	164
Figure 478: Discontinuation due to SEs.....	166
Figure 479: Discontinuation due to any reason including SE	167
Figure 480: Quality of life endpoint	169
Figure 481: Quality of life change score	169
More severe: Mirtazapine versus placebo	169
Figure 482: Depression symptomatology at endpoint	169
Figure 483: Depression symptomatology change score	169
Figure 484: Remission (ITT).....	170
Figure 485: Response (ITT).....	170
Figure 486: Discontinuation due to SE	170
Figure 487: Discontinuation due to any reason including SE	171
Figure 488: Global functioning endpoint	171
More severe: Mirtazapine versus SSRIs	171
Figure 489: Depression symptomatology endpoint	171
Figure 490: Depression symptomatology change score	172
Figure 491: Remission (ITT)	172
Figure 492: Response (ITT).....	173
Figure 493: Discontinuation due to SE	174
Figure 494: Discontinuation due to any reason including SE	175
More severe: Mirtazapine versus TCAs	175

Figure 495: Depression symptomatology endpoint	175
Figure 496: Depression symptomatology change score	176
Figure 497: Response (ITT).....	176
Figure 498: Discontinuation due to SE	177
Figure 499: Discontinuation due to any reason including SE	177
Figure 500: Global functioning endpoint	178
More severe: Mirtazapine versus venlafaxine	178
Figure 501: Depression symptomatology endpoint	178
Figure 502: Depression symptomatology change score	178
Figure 503: Remission (ITT).....	178
Figure 504: Response (ITT).....	178
Figure 505: Discontinuation due to SE	179
Figure 506: Discontinuation due to any reason including SE	179
Figure 507: Sleeping difficulties change score.....	179
More severe: Mirtazapine versus trazodone	179
Figure 508: Response (ITT).....	179
Figure 509: Discontinuation due to SE	179
Figure 510: Discontinuation due to any reason including SE	180
Figure 511: Global functioning endpoint	180
More severe: Trazodone versus placebo.....	180
Figure 512: Depression symptomatology endpoint	180
Figure 513: Depression symptomatology change score	180
Figure 514: Remission (ITT).....	180
Figure 515: Response (ITT).....	181
Figure 516: Discontinuation due to SE	181
Figure 517: Discontinuation due to any reason including SE	181
Figure 518: Sleeping difficulties change score.....	181
More severe: Trazodone versus SSRIs	182
Figure 519: Depression symptomatology endpoint	182
Figure 520: Depression symptomatology change score	182
Figure 521: Remission (ITT).....	183
Figure 522: Response (ITT).....	183
Figure 523: Discontinuation due to SE	184
Figure 524: Discontinuation due to any reason including SE	184
More severe: Trazodone versus TCAs	185
Figure 525: Depression symptomatology at endpoint	185
Figure 526: Depression symptomatology change score	185
Figure 527: Response (ITT).....	186
Figure 528: Discontinuation due to SE	186
Figure 529: Discontinuation due to any reason including SE	187

More severe: Trazodone versus venlafaxine	187
Figure 530: Depression symptomatology endpoint	187
Figure 531: Depression symptomatology change score	187
Figure 532: Remission (ITT)	188
Figure 533: Response (ITT).....	188
Figure 534: Discontinuation due to SE	188
Figure 535: Discontinuation due to any reason including SE	188
More severe: Trazodone + CBT individual versus placebo + CBT individual	188
Figure 536: Depression symptomatology endpoint	188
Figure 537: Response (ITT).....	189
Figure 538: Discontinuation due to SE	189
Figure 539: Discontinuation due to any reason including SE	189
More severe: Trazodone + CBT individual versus amitriptyline + CBT individual	189
Figure 540: Depression symptomatology endpoint	189
Figure 541: Response (ITT).....	189
Figure 542: Discontinuation due to SE	190
Figure 543: Discontinuation due to any reason including SE	190
More severe: Supervised high intensity exercise individual versus no treatment	190
Figure 544: Depression symptomatology endpoint	190
Figure 545: Depression symptomatology change score	190
Figure 546: Remission (ITT)	190
Figure 547: Discontinuation due to any reason.....	191
Figure 548: Quality of life endpoint	191
More severe: Exercise individual versus SSRI.....	191
Figure 549: Depression symptomatology endpoint	191
Figure 550: Depression symptomatology change score	191
Figure 551: Remission (ITT).....	192
Figure 552: Discontinuation due to any reason.....	192
Figure 553: Remission at 6-12 month follow-up (ITT)	192
Figure 554: Quality of life endpoint	193
More severe: Exercise individual + AD versus AD	193
Figure 555: Depression symptomatology endpoint	193
Figure 556: Depression symptomatology change score	193
Figure 557: Remission (ITT)	194
Figure 558: Response (ITT).....	194
Figure 559: Discontinuation due to SE	194
Figure 560: Discontinuation due to any reason including SE	194
Figure 561: Remission at 6-month follow-up (ITT)	195
Figure 562: Quality of life endpoint	195

More severe: Supervised high intensity exercise individual + sertraline versus no treatment.....	195
Figure 563: Depression symptomatology endpoint.....	195
Figure 564: Depression symptomatology change score	195
More severe: Exercise group versus no treatment.....	196
Figure 565: Depression symptomatology endpoint.....	196
Figure 566: Depression symptomatology change score	196
Figure 567: Response (ITT).....	196
Figure 568: Discontinuation due to any reason.....	196
More severe: Supervised low/high intensity exercise group versus TAU	197
Figure 569: Depression symptomatology endpoint.....	197
Figure 570: Depression symptomatology change score	197
Figure 571: Response (ITT).....	197
Figure 572: Discontinuation due to any reason.....	197
More severe: Supervised high intensity exercise group versus sertraline	197
Figure 573: Depression symptomatology change score	197
Figure 574: Remission (ITT).....	198
Figure 575: Discontinuation due to any reason.....	198
Figure 576: Remission at 12-month follow-up (ITT)	198
More severe: Supervised high intensity exercise group versus unsupervised high intensity exercise individual.....	198
Figure 577: Depression symptomatology change score	198
Figure 578: Remission (ITT).....	198
Figure 579: Discontinuation due to any reason.....	199
Figure 580: Remission at 12-month follow-up (ITT)	199
More severe: Exercise group + SSRI versus SSRI	199
Figure 581: Depression symptomatology endpoint.....	199
Figure 582: Depression symptomatology change score	199
Figure 583: Remission (ITT).....	200
Figure 584: Discontinuation due to any reason.....	200
More severe: Yoga group versus waitlist	200
Figure 585: Depression symptomatology endpoint.....	200
Figure 586: Depression symptomatology change score	201
Figure 587: Discontinuation due to any reason.....	201
Figure 588: Quality of life endpoint	201
More severe: Yoga group versus imipramine.....	201
Figure 589: Depression symptomatology endpoint.....	201
Figure 590: Depression symptomatology change score	201
Figure 591: Remission (ITT).....	201
More severe: Yoga group + any AD versus any AD.....	202
Figure 592: Depression symptomatology endpoint.....	202

Figure 593: Depression symptomatology change score	202
Figure 594: Remission (ITT).....	202
More severe: Traditional acupuncture versus waitlist.....	202
Figure 595: Remission (ITT).....	202
Figure 596: Response (ITT).....	202
Figure 597: Discontinuation due to any reason.....	203
More severe: Acupuncture versus sham acupuncture	203
Figure 598: Depression symptomatology endpoint.....	203
Figure 599: Depression symptomatology change score	203
Figure 600: Remission (ITT).....	204
Figure 601: Response (ITT).....	204
Figure 602: Discontinuation due to any reason.....	205
Figure 603: Depression symptomatology change score at 1-month follow-up ...	205
Figure 604: Depression symptomatology change score at 3-month follow-up ...	205
Figure 605: Remission at 1-month follow-up (ITT).....	205
Figure 606: Remission at 3-month follow-up (ITT).....	206
Figure 607: Quality of life (physical health component) change score	206
Figure 608: Quality of life (mental health component) change score.....	206
Figure 609: Global functioning change score.....	206
More severe: Acupuncture versus SSRI	207
Figure 610: Depression symptomatology endpoint.....	207
Figure 611: Depression symptomatology change score	207
Figure 612: Response (ITT).....	208
Figure 613: Discontinuation due to any reason.....	208
More severe: Acupuncture versus TCA	209
Figure 614: Depression symptomatology endpoint.....	209
Figure 615: Depression symptomatology change score	209
Figure 616: Discontinuation due to SE	209
Figure 617: Discontinuation due to any reason including SE	209
More severe: Acupuncture + AD versus AD	210
Figure 618: Depression symptomatology endpoint.....	210
Figure 619: Depression symptomatology change score	211
Figure 620: Remission (ITT).....	211
Figure 621: Response (ITT).....	212
Figure 622: Discontinuation due to SE	212
Figure 623: Discontinuation due to any reason including SE	213
Figure 624: Depression symptomatology at 1-month follow-up.....	213
Figure 625: Depression symptomatology change score at 1-month follow-up ...	213
More severe: Bright light therapy versus fluoxetine.....	214
Figure 626: Depression symptomatology change score	214

Figure 627: Remission (ITT).....	214
Figure 628: Response (ITT).....	214
Figure 629: Discontinuation due to SE	214
Figure 630: Discontinuation due to any reason including SE	214
More severe: Bright light therapy versus pill placebo	215
Figure 631: Depression symptomatology change score	215
Figure 632: Remission (ITT).....	215
Figure 633: Response (ITT).....	215
Figure 634: Discontinuation due to SE	215
Figure 635: Discontinuation due to any reason including SE	215
More severe: Bright light therapy + AD versus AD.....	216
Figure 636: Depression v endpoint	216
Figure 637: Depression symptomatology change score	216
Figure 638: Remission (ITT).....	216
Figure 639: Response (ITT).....	217
Figure 640: Discontinuation due to SE	217
Figure 641: Discontinuation due to any reason including SE	217
More severe: Bright light therapy + fluoxetine versus pill placebo	218
Figure 642: Depression symptomatology change score	218
Figure 643: Remission (ITT).....	218
Figure 644: Response (ITT).....	218
Figure 645: Discontinuation due to SE	218
Figure 646: Discontinuation due to any reason including SE	218

Forest plots for first-line treatment of more severe depression

Appendix E – Forest plots

More severe: Behavioural activation (BA) individual versus no treatment

Figure 1: Remission (ITT)




Figure 2: Discontinuation (any reason)




Figure 3: Depression symptomatology at 9-month follow-up





Figure 4: Remission at 9-month follow-up (ITT)



More severe: Behavioural therapies individual versus cognitive and cognitive behavioural therapies individual

Figure 5: Depression symptomatology endpoint




Figure 6: Depression symptomatology change score




Figure 7: Remission (ITT)




Figure 8: Discontinuation (any reason)




Figure 9: Depression symptomatology at 2-6 month follow-up





Figure 10: Interpersonal functioning endpoint



More severe: Behavioural activation (BA) individual versus any psychotherapy

Figure 11: Depression symptomatology endpoint




Figure 12: Depression symptomatology change score




Figure 13: Remission (ITT)




Figure 14: Response (ITT)




Figure 15: Discontinuation (any reason)




Figure 16: Quality of life endpoint




Figure 17: Quality of life physical health component endpoint





Figure 18: Quality of life mental health component endpoint



More severe: Behavioural activation (BA) individual versus sertraline

Figure 19: Remission (ITT)




Figure 20: Response (ITT)




Figure 21: Discontinuation (any)




Figure 22: Remission at 8-month follow-up (ITT)








Figure 23: Response at 8-month follow-up (ITT)

More severe: Behavioural activation (BA) individual + amitriptyline versus amitriptyline

Figure 24: Depression symptomatology endpoint**Figure 25: Depression symptomatology change score****Figure 26: Depression symptomatology at 6-month follow-up**

More severe: Behavioural activation (BA) individual + any AD versus counselling + any AD

Figure 27: Depression symptomatology endpoint




Figure 28: Depression symptomatology change score





Figure 29: Discontinuation (any reason)



More severe: Behavioural activation (BA) individual + amitriptyline versus progressive muscle relaxation + amitriptyline

Figure 30: Depression symptomatology endpoint




Figure 31: Depression symptomatology change score






Figure 32: Depression symptomatology at 6-month follow-up

More severe: Coping with Depression course (group) versus waitlist

Figure 33: Discontinuation (any reason)

More severe: Cognitive and cognitive behavioural therapies individual versus no treatment

Figure 34: Depression symptomatology endpoint




Figure 35: Depression symptomatology change score




Figure 36: Remission (ITT)




Figure 37: Discontinuation (any reason)




Figure 38: Depression symptomatology at 3-6 month follow-up




Figure 39: Depression symptomatology at 9-month follow-up




Figure 40: Remission at 6-9 month follow-up (ITT)




Figure 41: Functional impairment endpoint





Figure 42: Functional impairment at 6-month follow-up



More severe: Cognitive and cognitive behavioural therapies individual versus waitlist

Figure 43: Depression symptomatology endpoint




Figure 44: Depression symptomatology change score





Figure 45: Discontinuation (any reason)



More severe: Cognitive and cognitive behavioural therapies individual versus TAU

Figure 46: Depression symptomatology endpoint




Figure 47: Depression symptomatology change score




Figure 48: Remission (ITT)




Figure 49: Discontinuation (any reason)




Figure 50: Depression symptomatology at 8-month follow-up




Figure 51: Interpersonal problems endpoint




Figure 52: Interpersonal problems at 8-month follow-up





Figure 53: Functional impairment endpoint



More severe: CBT individual (15 sessions or over) versus IPT

Figure 54: Depression symptomatology endpoint




Figure 55: Depression symptomatology change score




Figure 56: Remission (ITT)



Figure 57: Discontinuation (any reason)




Figure 58: Global functioning endpoint





Figure 59: Interpersonal problems endpoint



More severe: CBT individual (under 15 sessions) versus counselling

Figure 60: Depression symptomatology endpoint




Figure 61: Depression symptomatology change score




Figure 62: Discontinuation (any reason)




Figure 63: Depression symptomatology at 3-month follow-up




Figure 64: Depression symptomatology at 8-9 month follow-up




Figure 65: Interpersonal problems endpoint





Figure 66: Interpersonal problems at 8-month follow-up



More severe: CBT individual (under 15 sessions) versus computerised-CBT (CCBT)

Figure 67: Depression symptomatology endpoint




Figure 68: Depression symptomatology change score




Figure 69: Discontinuation (any reason)




Figure 70: Depression symptomatology at 3-month follow-up




Figure 71: Depression symptomatology at 9-month follow-up





Figure 72: Remission at 9-month follow-up (ITT)



More severe: Cognitive and cognitive behavioural therapies individual versus self-help with support

Figure 73: Depression symptomatology endpoint




Figure 74: Depression symptomatology change score




Figure 75: Remission (ITT)




Figure 76: Discontinuation (any reason)




Figure 77: Depression symptomatology at 3-month follow-up




Figure 78: Depression symptomatology at 6-month follow-up




Figure 79: Depression SD symptomatology change score at 3-month follow-up




Figure 80: Depression symptomatology change score at 6-month follow-up




Figure 81: Quality of life endpoint




Figure 82: Global functioning endpoint




Figure 83: Global functioning at 3-month follow-up




Figure 84: Global functioning at 6-month follow-up




Figure 85: Interpersonal problems endpoint




Figure 86: Interpersonal problems at 3-month follow-up





Figure 87: Interpersonal problems at 6-month follow-up



More severe: Dialectical behavioural therapy (DBT) individual versus CBT group (under 15 sessions)

Figure 88: Depression symptomatology endpoint





Figure 89: Depression symptomatology change score



More severe: Cognitive and cognitive behavioural therapies individual versus SSRI

Figure 90: Depression symptomatology endpoint




Figure 91: Depression symptomatology change score




Figure 92: Remission (ITT)




Figure 93: Discontinuation (any reason)




Figure 94: Quality of life endpoint





Figure 95: Functional impairment endpoint



More severe: Cognitive and cognitive behavioural therapies individual versus TCA

Figure 96: Depression symptomatology endpoint




Figure 97: Depression symptomatology change score




Figure 98: Remission (ITT)




Figure 99: Discontinuation (any reason)




Figure 100: Depression symptomatology at 1-month follow-up




Figure 101: Depression symptomatology at 12-month follow-up




Figure 102: Remission at 12-month follow-up (ITT)




Figure 103: Global functioning endpoint





Figure 104: Interpersonal problems endpoint



More severe: CBT individual (15 sessions or over) versus venlafaxine

Figure 105: Depression symptomatology endpoint




Figure 106: Depression symptomatology change score




Figure 107: Remission (ITT)




Figure 108: Response (ITT)





Figure 109: Discontinuation (any reason)



More severe: CBT individual (15 sessions or over) versus any AD

Figure 110: Depression symptomatology endpoint




Figure 111: Depression symptomatology change score




Figure 112: Remission (ITT)





Figure 113: Discontinuation (any reason)



More severe: CBT individual (15 sessions or over) versus pill placebo

Figure 114: Depression symptomatology endpoint




Figure 115: Depression symptomatology change score




Figure 116: Remission (ITT)




Figure 117: Discontinuation (any reason)



Figure 118: Global functioning endpoint





Figure 119: Interpersonal problems endpoint



More severe: Cognitive and cognitive behavioural therapies individual + AD versus AD

Figure 120: Depression symptomatology endpoint




Figure 121: Depression symptomatology change score




Figure 122: Remission (ITT)




Figure 123: Response (ITT)




Figure 124: Discontinuation due to SE




Figure 125: Discontinuation due to any reason (including SE)








Figure 126: Depression symptomatology at 3-month follow-up**Figure 127: Depression symptomatology at 6-12 month follow-up****Figure 128: Global functioning endpoint****Figure 129: Functional impairment endpoint**

More severe: Cognitive and cognitive behavioural therapies individual + SSRI versus TAU

Figure 130: Depression symptomatology endpoint




Figure 131: Depression symptomatology change score




Figure 132: Remission (ITT)




Figure 133: Discontinuation due to any reason




Figure 134: Quality of life endpoint





Figure 135: Functional impairment endpoint



More severe: CBT group (under 15 sessions) versus no treatment

Figure 136: Depression symptomatology endpoint




Figure 137: Depression symptomatology change score





Figure 138: Depression symptomatology at 6-month follow-up



More severe: CBT group (under 15 sessions) versus waitlist

Figure 139: Depression symptomatology endpoint




Figure 140: Depression symptomatology change score





Figure 141: Discontinuation due to any reason



More severe: CBT group (under 15 sessions) versus TAU

Figure 142: Depression symptomatology endpoint




Figure 143: Depression symptomatology change score




Figure 144: Discontinuation due to any reason





Figure 145: Remission at 9-month follow-up (ITT)



More severe: CBT group (under 15 sessions) versus behavioural activation (BA) group

Figure 146: Depression symptomatology endpoint




Figure 147: Discontinuation du to any reason





Figure 148: Depression symptomatology at 1-month follow-up



More severe: CBT group (under 15 sessions) versus cognitive bibliotherapy

Figure 149: Depression symptomatology endpoint




Figure 150: Depression symptomatology change score





Figure 151: Discontinuation due to any reason



Figure 152: Depression symptomatology at 2-month follow-up



More severe: CBT group (under 15 sessions) versus cognitive bibliotherapy with support

Figure 153: Depression symptomatology endpoint




Figure 154: Depression symptomatology change score




Figure 155: Discontinuation due to any reason





Figure 156: Depression symptomatology at 2-month follow-up



More severe: CBT group (under 15 sessions) versus fluoxetine

Figure 157: Depression symptomatology endpoint




Figure 158: Remission (ITT)



Figure 159: Response (ITT)



Figure 160: Discontinuation due to any reason




Figure 161: Depression symptomatology at 3-month follow-up




Figure 162: Remission at 3-month follow-up (ITT)




Figure 163: Response at 3-month follow-up (ITT)



Figure 164: Quality of life endpoint





Figure 165: Quality of life at 3-month follow-up



More severe: CBT group (under 15 sessions) versus any AD

Figure 166: Depression symptomatology endpoint




Figure 167: Depression symptomatology change score




Figure 168: Discontinuation due to any reason




Figure 169: Remission at 9-month follow-up (ITT)



More severe: CBT group (under 15 sessions) + any AD versus any AD

Figure 170: Depression symptomatology endpoint




Figure 171: Depression symptomatology change score




Figure 172: Discontinuation due to SE




Figure 173: Discontinuation due to any reason including SE





Figure 174: Depression symptomatology at 6-month follow-up



More severe: Problem solving individual versus waitlist

Figure 175: Depression symptomatology endpoint




Figure 176: Depression symptomatology change score




Figure 177: Discontinuation due to any reason





Figure 178: Depression symptomatology at 2-month follow-up



More severe: Problem solving individual versus attention placebo

Figure 179: Depression symptomatology endpoint




Figure 180: Depression symptomatology change score




Figure 181: Discontinuation due to any reason




Figure 182: Depression symptomatology at 3-month follow-up




Figure 183: Depression symptomatology at 6-month follow-up




Figure 184: Functional impairment endpoint




Figure 185: Functional impairment at 3-month follow-up





Figure 186: Functional impairment at 6-month follow-up



More severe: Problem solving individual versus counselling

Figure 187: Depression symptomatology at endpoint




Figure 188: Depression symptomatology change score




Figure 189: Remission (ITT)




Figure 190: Response (ITT)




Figure 191: Discontinuation due to any reason





Figure 192: Functional impairment at endpoint



More severe: Problem solving individual versus any SSRI

Figure 193: Depression symptomatology endpoint




Figure 194: Remission (ITT)




Figure 195: Discontinuation due to any reason




Figure 196: Depression symptomatology at 9-month follow-up





Figure 197: Remission at 9-month follow-up (ITT)



More severe: Problem solving individual versus amitriptyline

Figure 198: Depression symptomatology endpoint




Figure 199: Depression symptomatology change score




Figure 200: Remission (ITT)





Figure 201: Discontinuation due to any reason



More severe: Problem solving individual versus pill placebo

Figure 202: Depression symptomatology endpoint




Figure 203: Depression symptomatology change score




Figure 204: Remission (ITT)





Figure 205: Discontinuation due to any reason



More severe: Problem solving individual + any SSRI versus any SSRI

Figure 206: Depression symptomatology endpoint




Figure 207: Remission (ITT)



Figure 208: Discontinuation due to SE




Figure 209: Discontinuation due any reason including SE




Figure 210: Depression symptomatology at 9-month follow-up





Figure 211: Remission at 9-month follow-up (ITT)



More severe: Problem solving group versus waitlist

Figure 212: Depression symptomatology endpoint




Figure 213: Depression symptomatology change score




Figure 214: Remission (ITT)





Figure 215: Discontinuation due to any reason



More severe: Counselling versus no treatment

Figure 216: Depression symptomatology endpoint




Figure 217: Depression symptomatology change score




Figure 218: Response (ITT)




Figure 219: Discontinuation due to any reason




Figure 220: Depression symptomatology at 5-month follow-up




Figure 221: Response at 5-month follow-up (ITT)




Figure 222: Functional impairment endpoint





Figure 223: Functional impairment at 5-month follow-up



More severe: Counselling versus TAU

Figure 224: Depression symptomatology endpoint




Figure 225: Depression symptomatology change score




Figure 226: Discontinuation due to any reason




Figure 227: Depression symptomatology at 8-month follow-up




Figure 228: Interpersonal problems endpoint





Figure 229: Interpersonal problems at 8-month follow-up



More severe: Counselling versus computerised-CBT (CCBT)

Figure 230: Depression symptomatology endpoint




Figure 231: Depression symptomatology change score




Figure 232: Depression symptomatology at 3-month follow-up





Figure 233: Depression symptomatology at 9-month follow-up



More severe: Counselling versus any AD

Figure 234: Depression symptomatology endpoint




Figure 235: Remission (ITT)




Figure 236: Discontinuation due to any reason




Figure 237: Depression symptomatology at 10-month follow-up





Figure 238: Remission at 10 months follow-up (ITT)



More severe: IPT versus any AD

Figure 239: Depression symptomatology endpoint





Figure 240: Depression symptomatology change score



More severe: Interpersonal counselling individual versus any SSRI

Figure 241: Remission (ITT)





Figure 242: Discontinuation due to any reason



More severe: IPT versus imipramine

Figure 243: Depression symptomatology endpoint




Figure 244: Depression symptomatology change score




Figure 245: Remission (ITT)




Figure 246: Discontinuation due to any reason



Figure 247: Global functioning endpoint





Figure 248: Interpersonal problems endpoint



More severe: IPT versus pill placebo

Figure 249: Depression symptomatology endpoint




Figure 250: Depression symptomatology change score




Figure 251: Remission (ITT)



Figure 252: Discontinuation due to any reason



Figure 253: Global functioning endpoint





Figure 254: Interpersonal problems endpoint



More severe: IPT + AD versus AD

Figure 255: Depression symptomatology endpoint




Figure 256: Depression symptomatology change score




Figure 257: Remission (ITT)




Figure 258: Discontinuation due to SE




Figure 259: Discontinuation due to any reason including SE




Figure 260: Remission at 3-month follow-up (ITT)




Figure 261: Remission at 9-month follow-up (ITT)<Insert graphic title here>





Figure 262: Global functioning endpoint



More severe: IPT + any AD versus psychoeducation group + any AD

Figure 263: Depression symptomatology change score




Figure 264: Remission (ITT)




Figure 265: Discontinuation due to any reason




Figure 266: Remission at 3-month follow-up (ITT)





Figure 267: Remission at 9-month follow-up (ITT)



More severe: Computerised-CBT (CCBT) versus no treatment

Figure 268: Depression symptomatology endpoint




Figure 269: Depression symptomatology change score




Figure 270: Discontinuation due to any reason




Figure 271: Depression symptomatology at 3-month follow-up




Figure 272: Depression symptomatology at 9-month follow-up




Figure 273: Remission at 9-month follow-up (ITT)





Figure 274: Quality of life endpoint



More severe: Self-help versus waitlist

Figure 275: Depression symptomatology endpoint




Figure 276: Depression symptomatology change score




Figure 277: Remission (ITT)




Figure 278: Response (ITT)




Figure 279: Discontinuation due to any reason





Figure 280: Functional impairment endpoint



More severe: Computerised-CBT (CCBT) versus enhanced TAU

Figure 281: Depression symptomatology endpoint




Figure 282: Discontinuation due to any reason




Figure 283: Depression symptomatology at 6-month follow-up




Figure 284: Quality of life endpoint




Figure 285: Quality of life at 6-month follow-up





Figure 286: Quality of life at 12-month follow-up



More severe: Computerised attentional bias modification versus attention placebo

Figure 287: Depression symptomatology endpoint





Figure 288: Depression symptomatology change score



More severe: Self-help + AD versus AD

Figure 289: Depression symptomatology endpoint




Figure 290: Remission (ITT)




Figure 291: Response (ITT)




Figure 292: Discontinuation due to any reason




Figure 293: Quality of life physical health component endpoint




Figure 294: Quality of life mental health component endpoint




Figure 295: Depression symptomatology at 8-month follow-up




Figure 296: Depression symptomatology at 20-month follow-up




Figure 297: Remission at 8-month follow-up (ITT)




Figure 298: Remission at 20-month follow-up (ITT)




Figure 299: Quality of life physical health component at 8-month follow-up




Figure 300: Quality of life mental health component at 8-month follow-up




Figure 301: Quality of life physical health component at 20-month follow-up





Figure 302: Quality of life mental health component at 20-month follow-up



More severe: Computerised-CBT (CCBT) with support versus no treatment

Figure 303: Depression symptomatology endpoint




Figure 304: Depression symptomatology change score




Figure 305: Remission (ITT)




Figure 306: Discontinuation due to any reason





Figure 307: Quality of life endpoint



More severe: Self-help with support versus waitlist

Figure 308: Depression symptomatology endpoint




Figure 309: Depression symptomatology change score




Figure 310: Remission (ITT)




Figure 311: Response (ITT)




Figure 312: Discontinuation due to any reason




Figure 313: Quality of life endpoint




Figure 314: Functional impairment endpoint





Figure 315: Sleeping difficulties endpoint



More severe: Self-help with support versus self-help (without support)

Figure 316: Depression symptomatology endpoint




Figure 317: Depression symptomatology change score




Figure 318: Remission (ITT)




Figure 319: Discontinuation due to any reason




Figure 320: Depression symptomatology at 2-3 month follow-up




Figure 321: Depression symptomatology at 6-month follow-up




Figure 322: Quality of life endpoint




Figure 323: Quality of life at 3-month follow-up





Figure 324: Quality of life at 6-month follow-up



More severe: Short-term psychodynamic psychotherapies individual versus any psychotherapy

Figure 325: Depression symptomatology endpoint




Figure 326: Depression symptomatology change score





Figure 327: Discontinuation due to any reason



More severe: Short-term psychodynamic psychotherapy individual versus cognitive and cognitive behavioural therapies individual

Figure 328: Depression symptomatology endpoint




Figure 329: Depression symptomatology change score




Figure 330: Remission (ITT)




Figure 331: Discontinuation due to any reason




Figure 332: Quality of life endpoint




Figure 333: Quality of life physical health component endpoint




Figure 334: Quality of life mental health component endpoint




Figure 335: Interpersonal problems endpoint





Figure 336: Remission at 3-month follow-up (ITT)



More severe: Dynamic interpersonal therapy (DIT) individual versus cognitive bibliotherapy with support

Figure 337: Depression symptomatology endpoint




Figure 338: Depression symptomatology change score




Figure 339: Remission (ITT)




Figure 340: Discontinuation due to any reason




Figure 341: Quality of life endpoint





Figure 342: Interpersonal problems endpoint



More severe: Short-term psychodynamic psychotherapies individual versus fluoxetine

Figure 343: Depression symptomatology change score




Figure 344: Remission (ITT)




Figure 345: Discontinuation due to any reason





Figure 346: Global functioning change score



More severe: Short-term psychodynamic psychotherapy individual + any AD versus any AD

Figure 347: Depression symptomatology endpoint




Figure 348: Depression symptomatology change score





Figure 349: Quality of life endpoint



More severe: Short-term psychodynamic psychotherapy individual + AD versus counselling + AD

Figure 350: Depression symptomatology endpoint




Figure 351: Depression symptomatology change score




Figure 352: Remission (ITT)




Figure 353: Response (ITT)




Figure 354: Discontinuation due to any reason




Figure 355: Depression symptomatology at 3-6 month follow-up




Figure 356: Remission at 3-6 month follow-up (ITT)




Figure 357: Response at 3-6 month follow-up (ITT)




Figure 358: Functional impairment endpoint






Figure 359: Functional impairment at 3-month follow-up



More severe: Short-term psychodynamic psychotherapy group versus cognitive and cognitive behavioural therapies group

Figure 360: Remission (ITT)



More severe: Long-term psychodynamic psychotherapy individual versus fluoxetine

Figure 361: Depression symptomatology endpoint




Figure 362: Remission (ITT)





Figure 363: Discontinuation due to any reason



More severe: Long-term psychodynamic psychotherapy individual + fluoxetine versus fluoxetine

Figure 364: Depression symptomatology endpoint




Figure 365: Remission (ITT)





Figure 366: Discontinuation due to any reason



More severe: Music therapy group versus no treatment

Figure 367: Depression symptomatology at endpoint




Figure 368: Depression symptomatology change score





Figure 369: Discontinuation due to any reason



More severe: Peer support group versus any AD

Figure 370: Depression symptomatology endpoint




Figure 371: Depression symptomatology change score




Figure 372: Remission (ITT)




Figure 373: Discontinuation due to any reason



Figure 374: Depression symptomatology at 6-month follow-up




Figure 375: Remission at 6-month follow-up (ITT)



More severe: Peer support group + any AD versus any AD

Figure 376: Depression symptomatology endpoint




Figure 377: Depression symptomatology change score




Figure 378: Remission (ITT)




Figure 379: Discontinuation due to any reason




Figure 380: Depression symptomatology at 6-month follow-up





Figure 381: Remission at 6-month follow-up (ITT)



More severe: Psychoeducation group versus no treatment

Figure 382: Depression symptomatology endpoint




Figure 383: Depression symptomatology change score




Figure 384: Discontinuation due to any reason



More severe: Psychoeducation group + any AD versus any AD

Figure 385: Depression symptomatology change score




Figure 386: Remission (ITT)




Figure 387: Discontinuation due to any reason




Figure 388: Remission at 3-month follow-up (ITT)



Figure 389: Remission at 9-month follow-up (ITT)



More severe: Mindfulness-based cognitive therapy (MBCT) group versus no treatment

Figure 390: Depression symptomatology endpoint





Figure 391: Depression symptomatology change score



More severe: Progressive muscle relaxation + amitriptyline versus amitriptyline

Figure 392: Depression symptomatology endpoint




Figure 393: Depression symptomatology change score





Figure 394: Depression symptomatology at 6-month follow-up



More severe: SSRIs versus no treatment

Figure 395: Depression symptomatology endpoint




Figure 396: Depression symptomatology change score




Figure 397: Discontinuation due to any reason




Figure 398: Quality of life physical health component endpoint





Figure 399: Quality of life mental health component endpoint



More severe: SSRIs versus placebo

Figure 400: Depression symptomatology endpoint




Figure 402: Remission (ITT)




Figure 403: Response (ITT)




Figure 405: Discontinuation due to any reason including SE




Figure 406: Remission at 12-month follow-up (ITT)




Figure 407: Quality of life change score




Figure 408: Global functioning endpoint




Figure 409: Functional impairment change score





Figure 410: Sleeping difficulties change score endpoint



More severe: SSRIs versus TCAs

Figure 411: Depression symptomatology endpoint




Figure 412: Depression symptomatology change score




Figure 413: Remission (ITT)




Figure 414: Response (ITT)




Figure 415: Discontinuation due to SE




Figure 416: Discontinuation due to any reason including SE




Figure 417: Sleep endpoint





Figure 418: Functional impairment endpoint



More severe: Fluoxetine + long-term psychodynamic psychotherapy individual versus long-term psychodynamic psychotherapy individual

Figure 419: Depression symptomatology endpoint




Figure 420: Remission (ITT)





Figure 421: Discontinuation due to any reason



More severe: SSRI + psych intervention versus placebo + psych intervention

Figure 422: Depression symptomatology endpoint




Figure 423: Depression symptomatology change score




Figure 424: Remission (ITT)




Figure 425: Discontinuation due to SE





Figure 426: Discontinuation due to any reason including SE



More severe: Sertraline + supervised high intensity exercise individual versus supervised high intensity exercise individual

Figure 427: Depression symptomatology endpoint





Figure 428: Depression symptomatology change score



More severe: Fluoxetine + bright light therapy versus bright light therapy

Figure 429: Depression symptomatology change score




Figure 430: Remission (ITT)




Figure 431: Response (ITT)




Figure 432: Discontinuation due to SE




Figure 433: Discontinuation due to any reason including SE



More severe: TCAs versus placebo

Figure 434: Depression symptomatology endpoint




Figure 435: Depression symptomatology change score




Figure 436: Remission (ITT)




Figure 437: Response (ITT)




Figure 438: Discontinuation due to SE




Figure 439: Discontinuation due to any reason including SE




Figure 440: Depression symptomatology at 6-month follow-up




Figure 441: Global functioning endpoint




Figure 442: Quality of life change score




Figure 443: Quality of life physical health component endpoint




Figure 444: Quality of life mental health component endpoint





Figure 445: Interpersonal problems endpoint



More severe: TCA + psych intervention versus psych intervention

Figure 446: Depression symptomatology endpoint




Figure 447: Depression symptomatology change score




Figure 448: Remission (ITT)




Figure 449: Discontinuation due to any reason




Figure 450: Depression symptomatology at 1-month follow-up




Figure 451: Depression symptomatology at 12-month follow-up





Figure 452: Global functioning endpoint



More severe: TCA + psych intervention versus placebo + psych intervention

Figure 453: Depression symptomatology endpoint




Figure 454: Depression symptomatology change score




Figure 455: Remission (ITT)




Figure 456: Response (ITT)




Figure 457: Discontinuation due to SE




Figure 458: Discontinuation due to any reason including SE




Figure 459: Depression symptomatology at 1-month follow-up





Figure 460: Depression symptomatology at 6-month follow-up



More severe: SNRIs versus placebo

Figure 461: Depression symptomatology endpoint




Figure 462: Depression symptomatology change score




Figure 463: Remission (ITT)




Figure 464: Response (ITT)




Figure 465: Discontinuation due to SE




Figure 466: Discontinuation due to any reason including SE





Figure 467: Functional impairment change score



More severe: SNRIs versus TCAs

Figure 468: Depression symptomatology endpoint




Figure 469: Depression symptomatology change score




Figure 470: Remission (ITT)




Figure 471: Response (ITT)




Figure 472: Discontinuation due to SE





Figure 473: Discontinuation due to any reason including SE



More severe: SNRIs versus SSRIs

Figure 474: Depression symptomatology endpoint




Figure 475: Depression symptomatology change score




Figure 476: Remission (ITT)




Figure 477: Response (ITT)





Figure 478: Discontinuation due to SEs



0.01 0.1 1 10 100
Favours SNRI Favours SSRI

Figure 479: Discontinuation due to any reason including SE




Figure 480: Quality of life endpoint





Figure 481: Quality of life change score



More severe: Mirtazapine versus placebo

Figure 482: Depression symptomatology at endpoint




Figure 483: Depression symptomatology change score




Figure 484: Remission (ITT)




Figure 485: Response (ITT)




Figure 486: Discontinuation due to SE




Figure 487: Discontinuation due to any reason including SE





Figure 488: Global functioning endpoint



More severe: Mirtazapine versus SSRIs

Figure 489: Depression symptomatology endpoint




Figure 490: Depression symptomatology change score




Figure 491: Remission (ITT)




Figure 492: Response (ITT)




Figure 493: Discontinuation due to SE





Figure 494: Discontinuation due to any reason including SE



More severe: Mirtazapine versus TCAs

Figure 495: Depression symptomatology endpoint




Figure 496: Depression symptomatology change score




Figure 497: Response (ITT)




Figure 498: Discontinuation due to SE




Figure 499: Discontinuation due to any reason including SE





Figure 500: Global functioning endpoint



More severe: Mirtazapine versus venlafaxine

Figure 501: Depression symptomatology endpoint




Figure 502: Depression symptomatology change score




Figure 503: Remission (ITT)




Figure 504: Response (ITT)




Figure 505: Discontinuation due to SE




Figure 506: Discontinuation due to any reason including SE





Figure 507: Sleeping difficulties change score



More severe: Mirtazapine versus trazodone

Figure 508: Response (ITT)




Figure 509: Discontinuation due to SE




Figure 510: Discontinuation due to any reason including SE





Figure 511: Global functioning endpoint



More severe: Trazodone versus placebo

Figure 512: Depression symptomatology endpoint




Figure 513: Depression symptomatology change score




Figure 514: Remission (ITT)




Figure 515: Response (ITT)




Figure 516: Discontinuation due to SE




Figure 517: Discontinuation due to any reason including SE





Figure 518: Sleeping difficulties change score



More severe: Trazodone versus SSRIs

Figure 519: Depression symptomatology endpoint




Figure 520: Depression symptomatology change score




Figure 521: Remission (ITT)




Figure 522: Response (ITT)




Figure 523: Discontinuation due to SE





Figure 524: Discontinuation due to any reason including SE



More severe: Trazodone versus TCAs

Figure 525: Depression symptomatology at endpoint




Figure 526: Depression symptomatology change score




Figure 527: Response (ITT)




Figure 528: Discontinuation due to SE





Figure 529: Discontinuation due to any reason including SE



More severe: Trazodone versus venlafaxine

Figure 530: Depression symptomatology endpoint




Figure 531: Depression symptomatology change score




Figure 532: Remission (ITT)




Figure 533: Response (ITT)




Figure 534: Discontinuation due to SE





Figure 535: Discontinuation due to any reason including SE



More severe: Trazodone + CBT individual versus placebo + CBT individual

Figure 536: Depression symptomatology endpoint




Figure 537: Response (ITT)




Figure 538: Discontinuation due to SE





Figure 539: Discontinuation due to any reason including SE



More severe: Trazodone + CBT individual versus amitriptyline + CBT individual

Figure 540: Depression symptomatology endpoint




Figure 541: Response (ITT)




Figure 542: Discontinuation due to SE





Figure 543: Discontinuation due to any reason including SE



More severe: Supervised high intensity exercise individual versus no treatment

Figure 544: Depression symptomatology endpoint




Figure 545: Depression symptomatology change score




Figure 546: Remission (ITT)




Figure 547: Discontinuation due to any reason





Figure 548: Quality of life endpoint



More severe: Exercise individual versus SSRI

Figure 549: Depression symptomatology endpoint




Figure 550: Depression symptomatology change score




Figure 551: Remission (ITT)




Figure 552: Discontinuation due to any reason




Figure 553: Remission at 6-12 month follow-up (ITT)





Figure 554: Quality of life endpoint



More severe: Exercise individual + AD versus AD

Figure 555: Depression symptomatology endpoint




Figure 556: Depression symptomatology change score




Figure 557: Remission (ITT)




Figure 558: Response (ITT)




Figure 559: Discontinuation due to SE




Figure 560: Discontinuation due to any reason including SE




Figure 561: Remission at 6-month follow-up (ITT)





Figure 562: Quality of life endpoint



More severe: Supervised high intensity exercise individual + sertraline versus no treatment

Figure 563: Depression symptomatology endpoint





Figure 564: Depression symptomatology change score



More severe: Exercise group versus no treatment

Figure 565: Depression symptomatology endpoint




Figure 566: Depression symptomatology change score




Figure 567: Response (ITT)





Figure 568: Discontinuation due to any reason



More severe: Supervised low/high intensity exercise group versus TAU

Figure 569: Depression symptomatology endpoint




Figure 570: Depression symptomatology change score




Figure 571: Response (ITT)





Figure 572: Discontinuation due to any reason



More severe: Supervised high intensity exercise group versus sertraline

Figure 573: Depression symptomatology change score




Figure 574: Remission (ITT)




Figure 575: Discontinuation due to any reason





Figure 576: Remission at 12-month follow-up (ITT)



More severe: Supervised high intensity exercise group versus unsupervised high intensity exercise individual

Figure 577: Depression symptomatology change score




Figure 578: Remission (ITT)




Figure 579: Discontinuation due to any reason




Figure 580: Remission at 12-month follow-up (ITT)



More severe: Exercise group + SSRI versus SSRI

Figure 581: Depression symptomatology endpoint




Figure 582: Depression symptomatology change score




Figure 583: Remission (ITT)





Figure 584: Discontinuation due to any reason



More severe: Yoga group versus waitlist

Figure 585: Depression symptomatology endpoint




Figure 586: Depression symptomatology change score




Figure 587: Discontinuation due to any reason





Figure 588: Quality of life endpoint



More severe: Yoga group versus imipramine

Figure 589: Depression symptomatology endpoint




Figure 590: Depression symptomatology change score





Figure 591: Remission (ITT)



More severe: Yoga group + any AD versus any AD

Figure 592: Depression symptomatology endpoint




Figure 593: Depression symptomatology change score





Figure 594: Remission (ITT)



More severe: Traditional acupuncture versus waitlist

Figure 595: Remission (ITT)




Figure 596: Response (ITT)





Figure 597: Discontinuation due to any reason



More severe: Acupuncture versus sham acupuncture

Figure 598: Depression symptomatology endpoint




Figure 599: Depression symptomatology change score




Figure 600: Remission (ITT)




Figure 601: Response (ITT)




Figure 602: Discontinuation due to any reason




Figure 603: Depression symptomatology change score at 1-month follow-up




Figure 604: Depression symptomatology change score at 3-month follow-up




Figure 605: Remission at 1-month follow-up (ITT)




Figure 606: Remission at 3-month follow-up (ITT)




Figure 607: Quality of life (physical health component) change score




Figure 608: Quality of life (mental health component) change score





Figure 609: Global functioning change score



More severe: Acupuncture versus SSRI

Figure 610: Depression symptomatology endpoint




Figure 611: Depression symptomatology change score




Figure 612: Response (ITT)





Figure 613: Discontinuation due to any reason



More severe: Acupuncture versus TCA

Figure 614: Depression symptomatology endpoint




Figure 615: Depression symptomatology change score




Figure 616: Discontinuation due to SE





Figure 617: Discontinuation due to any reason including SE



More severe: Acupuncture + AD versus AD

Figure 618: Depression symptomatology endpoint




Figure 619: Depression symptomatology change score




Figure 620: Remission (ITT)




Figure 621: Response (ITT)




Figure 622: Discontinuation due to SE




Figure 623: Discontinuation due to any reason including SE




Figure 624: Depression symptomatology at 1-month follow-up





Figure 625: Depression symptomatology change score at 1-month follow-up



More severe: Bright light therapy versus fluoxetine

Figure 626: Depression symptomatology change score




Figure 627: Remission (ITT)




Figure 628: Response (ITT)



Figure 629: Discontinuation due to SE



Figure 630: Discontinuation due to any reason including SE



More severe: Bright light therapy versus pill placebo

Figure 631: Depression symptomatology change score




Figure 632: Remission (ITT)




Figure 633: Response (ITT)




Figure 634: Discontinuation due to SE




Figure 635: Discontinuation due to any reason including SE



More severe: Bright light therapy + AD versus AD

Figure 636: Depression v endpoint




Figure 637: Depression symptomatology change score




Figure 638: Remission (ITT)




Figure 639: Response (ITT)




Figure 640: Discontinuation due to SE





Figure 641: Discontinuation due to any reason including SE



More severe: Bright light therapy + fluoxetine versus pill placebo

Figure 642: Depression symptomatology change score




Figure 643: Remission (ITT)




Figure 644: Response (ITT)




Figure 645: Discontinuation due to SE





Figure 646: Discontinuation due to any reason including SE



1